Esketamine Practice Update: Implications for Treatment

Esketamine's Role in Depression Treatment

Esketamine, a derivative of ketamine, has emerged as a promising treatment for depression, particularly in cases resistant to traditional therapies. The recent practice update published in August 2026 provides critical insights into its application, potentially influencing how clinicians approach treatment protocols. This update emphasizes the drug's rapid antidepressant effects, which are particularly beneficial for patients with treatment-resistant depression (TRD).

The update highlights esketamine's mechanism of action, which involves the modulation of glutamatergic neurotransmission. This is distinct from traditional antidepressants that primarily target monoaminergic systems. By acting on the N-methyl-D-aspartate (NMDA) receptor, esketamine facilitates synaptic plasticity, which is thought to underlie its rapid therapeutic effects.

Policy and Research Implications

The practice update on esketamine underscores the necessity for clinicians to stay informed about evolving guidelines. As esketamine becomes more integrated into treatment plans for depression, healthcare providers must adapt to new protocols to ensure optimal patient outcomes. This includes understanding appropriate dosing, administration routes, and monitoring requirements to mitigate potential side effects.

Furthermore, the update calls for ongoing research into esketamine's long-term efficacy and safety profile. While short-term benefits are well-documented, there is a need for comprehensive studies that investigate sustained effects and potential risks associated with prolonged use.

Risks and Unknowns

Despite its promise, esketamine is not without risks. The update notes potential side effects such as dissociation, dizziness, and increased blood pressure, which require careful management. Additionally, the potential for misuse and dependency necessitates stringent controls and monitoring protocols.

Another area of concern is the accessibility of esketamine treatment. The high cost and need for administration in certified healthcare settings may limit access for some patients, raising questions about equity and availability in mental health care.

Future Directions

Looking ahead, the integration of esketamine into depression treatment regimens will likely continue to evolve. Future research should focus on optimizing treatment protocols, minimizing risks, and enhancing patient access. Policymakers and healthcare providers must collaborate to address these challenges, ensuring that esketamine's potential benefits are realized across diverse patient populations.

As the landscape of depression treatment shifts, esketamine represents a significant advancement. Its rapid action offers hope for patients who have not responded to other treatments, but it also demands careful consideration of its broader implications in clinical practice.

The 2025 Monotherapy Approval Changed the Practice Calculus

The FDA's own record of the decision shows the practical shift clinicians are now navigating: on January 21, 2025, the agency approved esketamine as a standalone treatment for adults with treatment-resistant depression, ending the requirement that it always be paired with a concurrent oral antidepressant. The supplemental approval rested on a phase 4, randomized, double-blind, placebo-controlled trial in which esketamine alone produced a statistically significant improvement on the Montgomery-Asberg Depression Rating Scale at four weeks. For patients who have already failed two or more oral antidepressants and cannot tolerate or access a third concurrent medication, monotherapy removes a real practical barrier: one prescription and one REMS-monitored visit, rather than coordinating two drugs on two different schedules.

The REMS restriction predates this expansion. Esketamine has required a certified healthcare setting and at least two hours of direct observation since its original March 2019 approval, and the monotherapy indication does not relax that monitoring requirement. Clinics weighing whether to add the monotherapy option to their protocols are therefore weighing the same infrastructure cost, monitored treatment rooms, trained staff, a two-hour block per dose, against a larger eligible population now that a second antidepressant is no longer a prerequisite.

Where This Fits Alongside Other 2026 Esketamine Findings

This practice update does not stand alone. A separate systematic review of long-term esketamine and ketamine safety found no cumulative organ toxicity or addiction signal across the studies it covered, which supports expanding monotherapy access without new long-term safety red flags. Separately, research on biomarker changes in low-dose ketamine for MDD and PTSD points toward objective markers that could eventually help clinicians predict which patients respond to the NMDA-receptor pathway esketamine also acts through, instead of relying on trial-and-error dosing.